SWM
RCUS icon

SeaCrest Wealth Management’s Arcus Biosciences RCUS Stock Holding History

SeaCrest Wealth Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-350
Closed -$4K – 2321
2018
Q2 		$4K Hold
350
– – ﹤0.01% 1884
2018
Q1 		$5K Buy
+350
New +$5.83K ﹤0.01% 1800

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SeaCrest Wealth Management's RCUS Position: Q3 2018 in Review

SeaCrest Wealth Management sold out of Arcus Biosciences (RCUS) in Q3 2018, closing a stake of 350 shares — an estimated $4K sold.

SeaCrest Wealth Management first reported a position in RCUS in Q1 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2018. 57 funds tracked by Wall St. Rank hold RCUS as of Q3 2018.

  • SeaCrest Wealth Management reported no remaining Arcus Biosciences position as of Q3 2018 after selling out during the quarter.
  • SeaCrest Wealth Management sold 350 Arcus Biosciences shares in Q3 2018, an estimated $4K.
  • SeaCrest Wealth Management first reported a position in Arcus Biosciences in Q1 2018 and held it in 2 quarters.
  • SeaCrest Wealth Management's Arcus Biosciences position peaked at $5K in Q1 2018.
  • 57 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2018.

Based on SeaCrest Wealth Management's 13F filing for Q3 2018, filed 14 Nov 2018.